Roche
Herceptin biosimilar set for Indian market
January 21, 2014Research and Development, Sales and Marketing Biocon, Herceptin, Roche, biosimilars, canmab
Biocon has said its generic version of Roche’s ageing breast cancer drug Herceptin will go on sale in India from …
Roche schizophrenia drug fails
January 21, 2014Research and Development, Sales and Marketing Roche, biopertin, schizophrenia
Roche’s investigational schizophrenia drug bitopertin has failed to help patients with the disorder’s negative symptoms when pitted against placebo. Two …
AZ bullish on its future – but analysts wary
January 15, 2014Sales and Marketing AstraZeneca, Roche, analysts, jp morgan
AstraZeneca is combating fears over its long-term future by assuring investors that it has the pipeline and the tenacity to …
Merck’s melanoma vaccine impresses
November 19, 2013Research and Development, Sales and Marketing MK-3475, Merck, Roche, melanoma
Merck has posted impressive results for its new melanoma vaccine MK-3475 as it looks to vie for a place in …
Roche signs $17 million immatics deal
November 15, 2013Research and Development, Sales and Marketing Cancer, Roche, immatics, lung, prostate
Roche is to pay German biotech company immatics $17 million to collaborate on the search for vaccines in various cancers, …
ImmunoGen stops cancer trial
November 6, 2013Research and Development, Sales and Marketing Cancer, IMGN901, Immunogen, Roche
Roche subsidiary ImmunoGen has abandoned a Phase II trial into small-cell lung cancer (SCLC) after deciding that it was not …
Samsung signs biologics deal with Roche
October 25, 2013Manufacturing and Production Korea, Roche, Samsung
Roche is leaving nothing to chance in its pursuit of the biologics drug market, adding to its internal investment programme …
The new paradigm in oncology drug marketing
October 21, 2013Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Herceptin, Roche, marketing, oncology
Twenty years ago drugs to treat cancer were made up of chemotherapy agents which are essentially ‘blunt tools’ against the …
Roche rules out merger talk
October 18, 2013Sales and Marketing Cancer, Herceptin, Novartis, Roche, merger
Roche has dismissed talk of merging with fellow Swiss manufacturer Novartis as it revealed its results for the last three …
Roche poised to get even bigger in biomanufacturing
October 15, 2013Manufacturing and Production Jobs, Merck, Roche, cuts
Roche plans to invest a massive 800 million Swiss francs ($882m) over the next five years to increase manufacturing capacity …
Global cancer crisis flagged in report
October 3, 2013Medical Communications, Research and Development, Sales and Marketing IPRI, Roche, wprld prevention alliance
A new report advocates the formation of a major industry-backed initiative to tackle the world’s growing cancer burden. Sponsored by …
NICE U-turn on MabThera
October 3, 2013Sales and Marketing MabThera, NHS, NICE, Roche
NICE is thinking about recommending Roche’s MabThera for a rare autoimmune condition – a move which represents a partial victory …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
